ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.00%
Brent Oil
76.495
0.00%
Bitcoin
98,315.32
0.11%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE

  6. Ose Immunotherapeutics Sa (0RAD) Cotización

Ose Immunotherapeutics Sa

Ose Immunotherapeutics Sa (0RAD)

LSE
4.12
0.00
(0.00%)
Cerrado 05 Enero 10:30AM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
4.12
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
3
0.00 Rango del Día 0.00
4.12 Rango de 52 semanas 4.12
Capitalización de Mercado [m]
89.202M
Precio Anterior
4.12
Precio de Apertura
-
Hora
3
@
7.58
(O)
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
138
Acciones en circulación
21,651,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-7.12
Beneficio por acción (BPA)
-1.06
turnover
2.23M
Beneficio neto
-23M

Acerca de Ose Immunotherapeutics Sa

Sector
Coml Physical, Biologcl Resh
Industria
Coml Physical, Biologcl Resh
Sitio web
www.ose-immuno.com
Sede
Nantes, Loire-atlantique, Fra
Fundado
-
Ose Immunotherapeutics Sa is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker 0RAD. The last closing price for Ose Immunotherapeutics was 4.12 €. Over the last year, Ose Immunotherapeutics shares have traded in a share price range of 4.12 € to 4.12 €.

Ose Immunotherapeutics currently has 21,651,000 shares in issue. The market capitalisation of Ose Immunotherapeutics is 89.20 € million. Ose Immunotherapeutics has a price to earnings ratio (PE ratio) of -7.12.

0RAD Últimas noticias

Más noticias

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO Un abstract clinique sur les...

18 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO A clinical abstract on the induction results from the CoTikiS...

18 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary...

11 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé OSE Immunotherapeutics annonce des avancées cliniques...

11 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant...

04 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif

OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif Nantes, France, le 2 décembre 2024...

02 Diciembre 2024
UK Regulatory

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

OSE Immunotherapeutics Strengthens Leadership and Executive Committee OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 – 6:00pm CET - OSE...

02 Diciembre 2024
UK Regulatory

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article...

04 Noviembre 2024
UK Regulatory

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la...

04 Noviembre 2024
UK Regulatory

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis OSE...

04 Noviembre 2024
UK Regulatory
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1004.124.124.121544.12DE
4004.124.124.121184.12DE
12004.124.124.121384.12DE
26004.124.124.121254.12DE
52004.124.124.124034.12DE
156004.124.124.127614.12DE
260004.124.124.128864.12DE

0RAD - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Ose Immunotherapeutics?
El precio actual de las acciones de Ose Immunotherapeutics es 4.12 €
¿Cuántas acciones de Ose Immunotherapeutics están en circulación?
Ose Immunotherapeutics tiene 21,651,000 acciones en circulación
¿Cuál es la capitalización de mercado de Ose Immunotherapeutics?
La capitalización de mercado de Ose Immunotherapeutics es EUR 89.2M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Ose Immunotherapeutics?
Ose Immunotherapeutics ha negociado en un rango de 4.12 € a 4.12 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Ose Immunotherapeutics?
El ratio precio/beneficio de Ose Immunotherapeutics es -7.12
¿Cuál es el ratio de efectivo a ventas de Ose Immunotherapeutics?
El ratio de efectivo a ventas de Ose Immunotherapeutics es 73.47
¿Cuál es la moneda de reporte de Ose Immunotherapeutics?
Ose Immunotherapeutics presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Ose Immunotherapeutics?
El último ingresos anual de Ose Immunotherapeutics es EUR 2.23M
¿Cuál es el último beneficio anual de Ose Immunotherapeutics?
El último beneficio anual de Ose Immunotherapeutics es EUR -23M
¿Cuál es la dirección registrada de Ose Immunotherapeutics?
La dirección registrada de Ose Immunotherapeutics es 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200
¿Cuál es la dirección del sitio web de Ose Immunotherapeutics?
La dirección del sitio web de Ose Immunotherapeutics es www.ose-immuno.com
¿En qué sector industrial opera Ose Immunotherapeutics?
Ose Immunotherapeutics opera en el sector COML PHYSICAL, BIOLOGCL RESH

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discusión

Ver feed completo
benz280c benz280c 7 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 13 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 14 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 17 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 23 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 24 minutos hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 28 minutos hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 31 minutos hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 31 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 34 minutos hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 36 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 39 minutos hace
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 40 minutos hace
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO
Pickme2 Pickme2 41 minutos hace
Stop wasting our time with your ongoing Manipulated nonsense.... Just read the S-1 
Filed with the sec.... 


ATMH
georgejjl georgejjl 42 minutos hace
The MABs are no where near being the standard of care for treating Alzheimer’s patients.
AVXL
benz280c benz280c 44 minutos hace
Phone died when responding to that. In summary, I think the 24/7 is multi-pronged. It is necessary for the kind of business that Veemost is and will be, which aligns it and will help it qualify for Gold. I do not recall it expressly said that Gold was reached and turned down. Not saying that didn't
GDVM
Sheepdog Sheepdog 58 minutos hace
Really? So you think the SEC is going to start arresting OTC Scammers and Pump/Dumpers? I hope so...about time.
GCAN
Hummingbird2 Hummingbird2 59 minutos hace
$GTII ~ Just listen in the first 5 mins about $GTII 🛫 after March? https://www.youtube.com/watch?v=Ag2f2rDlq5g
GTII
Jane1999 Jane1999 59 minutos hace
Here the CEO : https://www.wsj.com/market-data/quotes/CA/XCNQ/TWOH/company-people/executive-profile/149699
TWOH
Curious Bystander Curious Bystander 1 hora hace
The Expert Market was set up by the SEC for several very specific reasons. But you could generally say that a security lands in that market when a company is either UNABLE or UNWILLING to file certain SEC-required forms.

UNABLE or UNWILLING. Hmmmm…..I wonder which category Quantum
FLCX
CometNebula81 CometNebula81 1 hora hace
What is everyone's opinion on if or when dividends may be restored and if so what much would we be looking at in dividends? Let's you have 100,000 shares what would you be getting every year?
FNMA
Steady_T Steady_T 1 hora hace
Wouldn't the MABS have to be better than donepezil and memantine to get approved making them the new SOC?

That doesn't mean the MABS are selling well.
AVXL
mrwhippy458 mrwhippy458 1 hora hace
Somewhat true. Once it's at 250m OS, they need to bring that market cap up so we can start seeing dollars
ABQQ
CrossFireTrader CrossFireTrader 1 hora hace
Actually Alocations are given to Dealerships based on how many Vettes they have sold in prior years 25 years ago I lived in Los Angeles and there was a small city Montclair about 10 15 south of Pasadena there was a Dealership there Richard Hibbard Chevrolet and he got more Vettes than anyone in the
GDVM

Su Consulta Reciente

LSE
0RAD
Ose Immunotherapeutics
BITMOT
3112119
Efsf Fx 2.5% Dec27 Eur
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados